IndraLab
Statements
reach
"Treatment with 10 µM MK-2206, an Akt inhibitor widely used in the clinical trials for cancer indicated a significant decrease in the expression of phosphorylated Akt, Phosphorylated GSK-3α/β, claudin-5, ZO-1 and ZO-2 protein levels compared to DMSO-treated controls in HLECs (Fig. 5a–d)."
reach
"Increased phosphorylation of Akt (increased Akt activities) causes phosphorylation of GSK3β (suppression of GSK3β activities) at the serine 9 residue while reduced phosphorylation of Akt (reduced Akt activities) decreases levels of phosphorylation of GSK3β (increased GSK3β activities)."